Glenn Coleman bought $2,974 of CRL
EVP & Chief Financial Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. 10 shares at an average of $297.43, traded Sep 30, 2026, filed Oct 2, 2026.
Score components
- +22RoleCFO
- 0Trade size$3k at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001100682-26-000144, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | POpen-market purchase Common Stock | +10 | $297.43 | $2,974 | 27,762 | 10 d ago |
Related signals
Other insiders at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Shannon M Parisotto CEVP, Disc & Safety Assessment | $303k 981 shares | -17% | |
| 26Weak | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $126k 800 shares | -3% | |
| 22Weak | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $60k 400 shares | -2% | |
| 3Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | George Massaro director | $19k 140 shares | -2% | |
| 31Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $73k 500 shares | -2% | |
| 3Weak | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | George Massaro director | $20k 140 shares | -2% | |
| 41Moderate | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Joseph W LaPlume EVP, Corp Strategy & Develop | $715k 4,400 shares | -18% | |
| 41Moderate | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Birgit Girshick Corporate Executive VP & COO | $249k 1,514 shares | +3% | |
| 58Moderate | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | James C Foster Chairman, President and CEO | $1.0M 6,075 shares | +3% | |
| 50Moderate | CRLsell CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Richard F Wallman director | $1.6M 7,621 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.